AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15271105 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of 2% dorzolamide and 0.5% timolol
Number of subjects: 131
Study 15271105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination dorzolamide-timolol (Cosopt) in replacement study
Number of subjects: 131
Study 10746815 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 260
Study 10746815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 8698947 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 225
Study 8698947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Number of subjects: 225
Study 8698947 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine with clinical management
Number of subjects: 225
Study 8698947 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clinical management
Number of subjects: 225
Study 1614074 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg, single oral dose)
Number of subjects: 10
Study 1614074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6540130 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG therapy
Number of subjects: 1
Study 3487296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of verapamil prior to aortic cross‐clamping (Group 1)
Number of subjects: 0
Study 3487296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil plus verapamil in the cardioplegic solution (Group 2)
Number of subjects: 0
Study 3487296 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil in the cardioplegic solution only (Group 3)
Number of subjects: 0
Study 3487296 — intervention group
Group type: COMPARATOR
Intervention: No verapamil (Group 4)
Number of subjects: 0
Study 30464699 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes for physical function (pro-pf)
Number of subjects: 0
Study 30464699 — intervention group
Group type: COMPARATOR
Intervention: Objective measures of physical activity and fitness
Number of subjects: 0
Study 27388626 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 personalized motivational interviewing-based peer network counseling messages
Number of subjects: 200
Study 27388626 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention (general health habits text messages)
Number of subjects: 200
Study 24164779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose drinks (4 × 250 ml, total 1800 kJ/d)
Number of subjects: 41
Study 24164779 — intervention group
Group type: COMPARATOR
Intervention: Aspartame drinks (4 × 250 ml)
Number of subjects: 41
Study 24164779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose drinks
Number of subjects: 41
Study 24164779 — intervention group
Group type: COMPARATOR
Intervention: Sucrose drinks and Aspartame drinks
Number of subjects: 41
Study 22646315 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (feedback group)
Number of subjects: 60
Study 22646315 — intervention group
Group type: EXPERIMENTAL
Intervention: Group NF (no feedback group)
Number of subjects: 60
Study 22646315 — intervention group
Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 60
Study 19911170 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 g/kg)
Number of subjects: 0
Study 19911170 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 0
Study 19911170 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 0
Study 19911170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18093708 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated whole-body vibration (bandwidth=2-20 Hz, root-mean-squared amplitude=1.15m/s²)
Number of subjects: 21
Study 16189197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH (0.3 mg . kg(‐1) . d(‐1))
Number of subjects: 30
Study 16189197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16189197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH
Number of subjects: 30
Study 16189197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DEXA
Number of subjects: 30
Study 16189197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose DEXA
Number of subjects: 30
Study 12939889 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised utility assessment interview with individualized risk assessment and decision analysis
Number of subjects: 217
Study 12939889 — intervention group
Group type: EXPERIMENTAL
Intervention: Information video and leaflet about high blood pressure
Number of subjects: 217
Study 12939889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 217
Study 12939889 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 217
Study 10555606 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 0
Study 8554472 — intervention group
Group type: EXPERIMENTAL
Intervention: Roho cushion
Number of subjects: 14
Study 8554472 — intervention group
Group type: EXPERIMENTAL
Intervention: PU foam cushion
Number of subjects: 14
Study 8554472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 14
Study 1714507 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine riboside (MMPR) at 75 mg/m2
Number of subjects: 27
Study 1714507 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine riboside (MMPR) at 150 mg/m2
Number of subjects: 27
Study 1714507 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine riboside (MMPR) at 225 mg/m2
Number of subjects: 27
Study 6134137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (5 mg)
Number of subjects: 2
Study 6134137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30446250 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (n=151) for 12 weeks
Number of subjects: 307
Study 30446250 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (n=156) for 12 weeks
Number of subjects: 307
Study 28662526 — intervention group
Group type: EXPERIMENTAL
Intervention: Working conditions of physician assistants
Number of subjects: 26
Study 27015720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy adapted for adolescents (DBT-A)
Number of subjects: 77
Study 27015720 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 77
Study 24768191 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 1 g/d
Number of subjects: 18
Study 24768191 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin with laropiprant (ERN/LRP) 1 g/20 mg
Number of subjects: 18
Study 24768191 — intervention group
Group type: COMPARATOR
Intervention: Control (washout period)
Number of subjects: 18
Study 22878133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130
Study 22878133 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 130
Study 19892318 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session intervention with access to safety aids during early exposure trials
Number of subjects: 0
Study 19892318 — intervention group
Group type: COMPARATOR
Intervention: Single-session intervention without access to safety aids during early exposure trials
Number of subjects: 0
Study 18028041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 529
Study 18028041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 16187006 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PC) 24 mg/kg b.w.
Number of subjects: 68
Study 16187006 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 20 mg/kg b.w.
Number of subjects: 68
Study 11696738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine
Number of subjects: 205
Study 11696738 — intervention group
Group type: COMPARATOR
Intervention: 2.7% sorbitol-0.5% mannitol
Number of subjects: 205
Study 9161626 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for seven days
Number of subjects: 419
Study 9161626 — intervention group
Group type: COMPARATOR
Intervention: No antiviral therapy
Number of subjects: 419
Study 9161626 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for seven days among patients 50 years or older
Number of subjects: 419
Study 7929515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical management with splint appliance (group 2, n = 8)
Number of subjects: 29
Study 7929515 — intervention group
Group type: EXPERIMENTAL
Intervention: Commissuroplasty (group 3, n = 9)
Number of subjects: 29
Study 7929515 — intervention group
Group type: COMPARATOR
Intervention: No surgery and no splint (group 1, n = 21)
Number of subjects: 29
Study 3367744 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐5
Number of subjects: 8
Study 3367744 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐6
Number of subjects: 8
Study 3367744 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐7.5
Number of subjects: 8
Study 3367744 — intervention group
Group type: COMPARATOR
Intervention: WP
Number of subjects: 8
Study 3367744 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO trials (CHO‐5, CHO‐6, CHO‐7.5)
Number of subjects: 8
Study 30171698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel once-daily application three times per week for 4 weeks
Number of subjects: 217
Study 30171698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel seven times within 2 weeks
Number of subjects: 217
Study 30171698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel five times for 1 week
Number of subjects: 217
Study 30171698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Number of subjects: 217
Study 30171698 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% resiquimod gel three times per week up to a biological end point or for a maximum duration of 8 weeks
Number of subjects: 217
Study 30171698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 28965908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (theoretical and practical workshop using a phantom)
Number of subjects: 20
Study 28965908 — intervention group
Group type: COMPARATOR
Intervention: No training (Group B)
Number of subjects: 20
Study 25833957 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin 90 mg/m2
Number of subjects: 1206
Study 25833957 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin 60 mg/m2
Number of subjects: 1206
Study 24175460 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific practice with a soccer ball
Number of subjects: 41
Study 24175460 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific practice with 1 kg balls
Number of subjects: 41
Study 24175460 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice with 0.35, 0.45, 0.5, and 1 kg balls
Number of subjects: 41
Study 21151020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 157
Study 21151020 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 157
Study 19167733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg per day) during oral phase A
Number of subjects: 159
Study 19167733 — intervention group
Group type: COMPARATOR
Intervention: Placebo during oral phase A
Number of subjects: 159
Study 19167733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg per day) during oral phase B
Number of subjects: 159
Study 19167733 — intervention group
Group type: COMPARATOR
Intervention: Placebo during oral phase B
Number of subjects: 159
Study 19167733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide and Placebo (both phases)
Number of subjects: 159
Study 17472863 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 0
Study 17472863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 0
Study 17472863 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14641105 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/day for 8 weeks
Number of subjects: 26
Study 14641105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11248742 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at a mean dose of 0.32 mg/kg per week for 1 year
Number of subjects: 8
Study 11248742 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment serum total IGF‐I levels
Number of subjects: 8
Study 11248742 — intervention group
Group type: COMPARATOR
Intervention: Serum free IGF‐I levels
Number of subjects: 8
Study 11248742 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary IGFBPs (IGFBP‐2, IGFBP‐3, ALS)
Number of subjects: 8
Study 11248742 — intervention group
Group type: COMPARATOR
Intervention: Serum IGFBP‐3 levels
Number of subjects: 8
Study 9134464 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Nursing
Number of subjects: 850
Study 9134464 — intervention group
Group type: COMPARATOR
Intervention: Lagged Experimental Group (Control)
Number of subjects: 850
Study 8201372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate 60 mg three times per day orally
Number of subjects: 291
Study 8201372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood tests (Haemoccult)
Number of subjects: 154
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Double contrast barium enema (DCBE)
Number of subjects: 154
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibresigmoidoscopy
Number of subjects: 154
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 154
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibresigmoidoscopy and DCBE used together
Number of subjects: 154
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood tests and DCBE alone
Number of subjects: 154
Study 3251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibresigmoidoscopy and DCBE used in conjunction
Number of subjects: 154
Study 30562088 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention optical coherence tomography examination
Number of subjects: 386
Study 30562088 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month follow-up optical coherence tomography examination
Number of subjects: 386
Study 27978867 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT diet
Number of subjects: 117
Study 27978867 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 117
Study 26098419 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata (RC) 250 mg twice/day (n=38)
Number of subjects: 57
Study 26098419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg twice/day) (n=19)
Number of subjects: 57
Study 24206155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad training
Number of subjects: 50
Study 24206155 — intervention group
Group type: COMPARATOR
Intervention: Directed self-regulated learning (DSRL)
Number of subjects: 50
Study 22165036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 140
Study 22165036 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone
Number of subjects: 140
Study 19894330 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1500 g/day + alfacalcidol 0.5 mg/day
Number of subjects: 42
Study 19894330 — intervention group
Group type: COMPARATOR
Intervention: Calcium 1500 g/day + placebo
Number of subjects: 42
Study 16720058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (25 mg/m2 on days 1 and 8) and cisplatin (80 mg/m2 on day 8) every 3 weeks
Number of subjects: 32
Study 16720058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and cisplatin
Number of subjects: 32
Study 15100375 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hemoglobin group (target hemoglobin of 14 +/- 1 g/dl)
Number of subjects: 35
Study 15100375 — intervention group
Group type: COMPARATOR
Intervention: Anemic hemoglobin group (target hemoglobin of 10 +/- 1 g/dl)
Number of subjects: 35
Study 11529973 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (T)
Number of subjects: 283
Study 11529973 — intervention group
Group type: COMPARATOR
Intervention: sequential methotrexate and 5-fluorouracil (MF)
Number of subjects: 283
Study 8547417 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (1 megaunit weekly for 4 weeks)
Number of subjects: 30
Study 2501813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (Nicorette; average of 6.9 pieces per day)
Number of subjects: 40
Study 2501813 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 40
Study 73312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% proflavine in 100% DMSO
Number of subjects: 56
Study 73312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% neutral red in 100% DMSO
Number of subjects: 56
Study 73312 — intervention group
Group type: COMPARATOR
Intervention: 1% picric acid in 100% DMSO (placebo)
Number of subjects: 56
Study 73312 — intervention group
Group type: COMPARATOR
Intervention: 1% color ruber in 100% DMSO (placebo)
Number of subjects: 56
Study 30496578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D3 (adjusted to maintain serum 25(OH)D >75 nmol/L)
Number of subjects: 260
Study 30496578 — intervention group
Group type: COMPARATOR
Intervention: Placebo vitamin D3
Number of subjects: 260
Study 27100724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 0
Study 27100724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26034983 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM self‐monitoring combined with weekly PA‐focused feedback sessions
Number of subjects: 102
Study 26034983 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM self‐monitoring combined with six weekly sessions without feedback
Number of subjects: 102
Study 26034983 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 102
Study 24955642 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (2 mg/day) combined with collagen hydrolysate (3 g/day)
Number of subjects: 44
Study 24955642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24955642 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin and collagen hydrolysate
Number of subjects: 44
Study 22499290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortalidone (12.5-25 mg daily)
Number of subjects: 2409
Study 22499290 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive medications (excluding thiazides)
Number of subjects: 2409
Study 20634226 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based mutual peer support intervention
Number of subjects: 54
Study 17620073 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year subcutaneous specific immunotherapy (SIT) with standardized allergen extracts of grass and/or birch
Number of subjects: 147
Study 17620073 — intervention group
Group type: COMPARATOR
Intervention: No specific immunotherapy (Control)
Number of subjects: 147
Study 17620073 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (3-year course)
Number of subjects: 147
Study 17620073 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 147
Study 16297693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% to 3%)
Number of subjects: 86
Study 16297693 — intervention group
Group type: COMPARATOR
Intervention: Halothane (1% to 1.5%)
Number of subjects: 86
Study 11991793 — intervention group
Group type: EXPERIMENTAL
Intervention: E. purpurea/E. angustifolia (EPA)
Number of subjects: 48
Study 11991793 — intervention group
Group type: EXPERIMENTAL
Intervention: E. purpurea/E. angustifolia plus larch arabinogalactan (EPALA)
Number of subjects: 48
Study 11991793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9836561 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular androgen ablation (bilateral orchiectomy in 15 and luteinizing hormone‐releasing hormone analogue in 3)
Number of subjects: 18
Study 9836561 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg/day) alone or in combination with flutamide (250 mg three times a day)
Number of subjects: 18
Study 9094865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 100
Study 9094865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1918555 — intervention group
Group type: EXPERIMENTAL
Intervention: General coping preparation package (PREP)
Number of subjects: 60
Study 1918555 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training with guided relaxation imagery (RT)
Number of subjects: 60
Study 1918555 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RT and PREP
Number of subjects: 60
Study 1918555 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic treatment only
Number of subjects: 60
Study 6173904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (MOPP + LDB)
Number of subjects: 136
Study 6173904 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (MOPP + LDB + XRT)
Number of subjects: 136
Study 6173904 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 136
Study 30902420 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg (400 IU) vitamin D supplementation
Number of subjects: 975
Study 30902420 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg (1200 IU) vitamin D supplementation
Number of subjects: 975
Study 30902420 — intervention group
Group type: EXPERIMENTAL
Intervention: High cord blood 25-hydroxyvitamin D (≥100 nmol/L)
Number of subjects: 975
Study 28374661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation group (MBPEG)
Number of subjects: 342